TI
ZNTL icon

Trexquant Investment’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Trexquant Investment’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-37,830
Closed -$596K – 1908
2024
Q1 		$596K Buy
+37,830
New +$520K 0.01% 1097
2023
Q4 		– Sell
-24,516
Closed -$492K – 1864
2023
Q3 		$492K Sell
24,516
-15,942
-39% -$405K 0.01% 1028
2023
Q2 		$1.14M Buy
40,458
+17,371
+75% +$417K 0.03% 714
2023
Q1 		$397K Buy
+23,087
New +$468K 0.01% 1088
2022
Q3 		– Sell
-7,298
Closed -$205K – 1901
2022
Q2 		$205K Buy
7,298
+1,323
+22% +$35K 0.01% 1345
2022
Q1 		$276K Sell
5,975
-9,086
-60% -$490K 0.01% 1050
2021
Q4 		$1.27M Buy
+15,061
New +$1.17M 0.08% 328
2021
Q3 		– Sell
-5,969
Closed -$318K – 1546
2021
Q2 		$318K Buy
+5,969
New +$320K 0.03% 685
2021
Q1 		– Sell
-6,798
Closed -$353K – 1528
2020
Q4 		$353K Buy
+6,798
New +$307K 0.04% 603

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Trexquant Investment's ZNTL Position: Q2 2024 in Review

Trexquant Investment sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2024, closing a stake of 37,830 shares — an estimated $596K sold.

Trexquant Investment first reported a position in ZNTL in Q4 2020 and held it in 9 quarters. The position peaked at $1.27M in Q4 2021. 145 funds tracked by Wall St. Rank hold ZNTL as of Q2 2024.

  • Trexquant Investment reported no remaining Zentalis Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Trexquant Investment sold 37,830 Zentalis Pharmaceuticals shares in Q2 2024, an estimated $596K.
  • Trexquant Investment first reported a position in Zentalis Pharmaceuticals in Q4 2020 and held it in 9 quarters.
  • Trexquant Investment's Zentalis Pharmaceuticals position peaked at $1.27M in Q4 2021.
  • 145 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2024.

Based on Trexquant Investment's 13F filing for Q2 2024, filed 13 Aug 2024.